Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

201. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.

Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557311 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):799-800. doi: 10.1056/NEJMc1607939#SA2. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. 1 , 1 , 1 . 1 12 Octubre Hospital, Madrid, Spain jbareamendoza@gmail.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID

NEJM2016 Full Text: Link to full Text with Trip Pro

202. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.

Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557312 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):800. doi: 10.1056/NEJMc1607939#SA3. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. 1 . 1 Ottawa Hospital Research Institute, Ottawa, ON, Canada asorisky@ohri.ca. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID

NEJM2016 Full Text: Link to full Text with Trip Pro

203. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.

Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557313 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):800-1. doi: 10.1056/NEJMc1607939#SA4. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. 1 , 2 . 1 University of New Mexico Health Sciences Center, Albuquerque, NM. 2 Christus St. Vincent Regional Medical Center, Santa Fe, NM irw.hoffman

NEJM2016 Full Text: Link to full Text with Trip Pro

204. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery.

Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27557309 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 25;375(8):801. doi: 10.1056/NEJMc1607939. Rate Control or Rhythm Control for Atrial Fibrillation after Heart Surgery. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27557309 DOI: [Indexed

NEJM2016

205. A case report of systemic embolic events associated with atrial fibrillation

A case report of systemic embolic events associated with atrial fibrillation 29123849 2018 11 13 2052-8817 4 1 2017 01 Acute medicine & surgery Acute Med Surg A case report of systemic embolic events associated with atrial fibrillation. 127-130 10.1002/ams2.235 An 82-year-old woman who had atrial fibrillation was found unconscious and was brought to the emergency department by ambulance. Her Glasgow Coma Scale score was 3, and an electrocardiogram showed ST segment elevation in V3 and V4 (...) . Cardiac ultrasonography showed left ventricular asynergy in the anterior wall, septum, and apex. Although dissection of the aorta was suspected, contrast computed tomography showed multiple arterial thromboses, including bilateral common carotid arteries and poor contrast in the left ventricle. Diffusion-weighted images of magnetic resonance imaging showed a diffuse high-intensity area in both cerebral cortices. The diagnosis was multiple arterial thromboembolisms associated with atrial fibrillation

Acute medicine & surgery2016 Full Text: Link to full Text with Trip Pro

206. Stroke prevention in atrial fibrillation.

Stroke prevention in atrial fibrillation. Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fibrillation monitoring. Data from stroke registries show that both unknown and untreated or under treated atrial fibrillation is responsible for most of these strokes, which are often fatal or debilitating. Most could be prevented if efforts were directed towards detection of atrial fibrillation before stroke occurs, through screening or case finding (...) , and treatment of all patients with atrial fibrillation at increased risk of stroke with well-controlled vitamin K antagonists or non-vitamin K antagonist anticoagulants. The default strategy should be to offer anticoagulant thromboprophylaxis to all patients with atrial fibrillation unless defined as truly low risk by simple validated risk scores, such as CHA2DS2-VASc. Assessment of bleeding risk using the HAS-BLED score should focus attention on reversible bleeding risk factors. Finally, patients need

Lancet2016

207. Rate control in atrial fibrillation.

Rate control in atrial fibrillation. Control of the heart rate (rate control) is central to atrial fibrillation management, even for patients who ultimately require control of the rhythm. We review heart rate control in patients with atrial fibrillation, including the rationale for the intervention, patient selection, and the treatments available. The choice of rate control depends on the symptoms and clinical characteristics of the patient, but for all patients with atrial fibrillation, rate (...) cautiously. Atrioventricular node ablation with pacemaker insertion for rate control should be used as an approach of last resort but is also an option early in the management of patients with atrial fibrillation treated with cardiac resynchronisation therapy. However, catheter ablation of atrial fibrillation should be considered before atrioventricular node ablation. Although rate control is a top priority and one of the first management issues for all patients with atrial fibrillation, many issues

Lancet2016

208. Rhythm control in atrial fibrillation.

Rhythm control in atrial fibrillation. Many patients with atrial fibrillation have substantial symptoms despite ventricular rate control and require restoration of sinus rhythm to improve their quality of life. Acute restoration (ie, cardioversion) and maintenance of sinus rhythm in patients with atrial fibrillation are referred to as rhythm control. The decision to pursue rhythm control is based on symptoms, the type of atrial fibrillation (paroxysmal, persistent, or long-standing persistent (...) ), patient comorbidities, general health status, and anticoagulation status. Many patients have recurrent atrial fibrillation and require further intervention to maintain long term sinus rhythm. Antiarrhythmic drug therapy is generally recommended as a first-line therapy and drug selection is on the basis of the presence or absence of structural heart disease or heart failure, electrocardiographical variables, renal function, and other comorbidities. In patients who continue to have recurrent

Lancet2016

209. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.

Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. BACKGROUND: Atrial fibrillation is an important cause of morbidity and mortality worldwide, but scant data are available for long-term outcomes in individuals outside North America or Europe, especially in primary care settings. METHODS: We did a cohort study using a prospective registry of patients in 47 countries who presented to a hospital emergency department (...) with atrial fibrillation or atrial flutter as a primary or secondary diagnosis. 15 400 individuals were enrolled to determine the occurrence of death and strokes (the primary outcomes) in this cohort over eight geographical regions (North America, western Europe, and Australia; South America; eastern Europe; the Middle East and Mediterranean crescent; sub-Saharan Africa; India; China; and southeast Asia) 1 year after attending the emergency department. Patients from North America, western Europe, and Australia were

Lancet2016

210. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists

Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists 27172860 2016 09 25 2016 09 25 1538-7836 14 9 2016 Sep Journal of thrombosis and haemostasis : JTH J. Thromb. Haemost. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. 1715-24 10.1111/jth.13361 Essentials Under-treatment of oral anticoagulation in the elderly with atrial fibrillation is common. As bleeding prediction (...) is challenging, we compared HAS-BLED, ATRIA and HEMORR2 HAGES. All three were associated with major bleeding in the elderly, but with poor predictive abilities. Future studies with focus on elderly-specific risk factors for bleeding are warranted. Background Anticipated bleeding complications contribute to underuse of oral anticoagulants, especially in elderly patients with atrial fibrillation (AF). Bleeding risk models could provide guidance; however, these were developed in the general AF population

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

211. Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation

Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation P Percutaneous endoscopic laser balloon ercutaneous endoscopic laser balloon pulmonary v pulmonary vein isolation for atrial fibrillation ein isolation for atrial fibrillation Interventional procedures guidance Published: 27 July 2016 nice.org.uk/guidance/ipg563 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available (...) reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 81 1 Recommendations Recommendations 1.1 Current evidence on the safety of percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation shows there are serious but well-recognised complications. Evidence on efficacy is adequate in quantity and quality to support the use of this procedure provided that standard arrangements are in place for clinical governance

National Institute for Health and Clinical Excellence - Interventional Procedures2016

212. Reduction of Fluoroscopy Time and Radiation Dosage During Catheter Ablation for Atrial Fibrillation

Reduction of Fluoroscopy Time and Radiation Dosage During Catheter Ablation for Atrial Fibrillation 27617094 2016 09 12 2018 11 13 2050-3369 5 2 2016 Aug Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Reduction of Fluoroscopy Time and Radiation Dosage During Catheter Ablation for Atrial Fibrillation. 144-9 10.15420/AER.2016.16.2 Radiofrequency catheter ablation has become the treatment of choice for atrial fibrillation (AF) that does not respond to antiarrhythmic drug therapy (...) and should learn how to decrease radiation exposure by both changing the setting of the system and using complementary imaging technologies. In this review, we aim to discuss the basics of X-ray exposure and suggest practical instructions for how to reduce radiation dosage during AF ablation procedures. Yamagata Kenichiro K Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Aldhoon Bashar B Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic

Arrhythmia & electrophysiology review2016 Full Text: Link to full Text with Trip Pro

213. Individualising Anticoagulant Therapy in Atrial Fibrillation Patients

Individualising Anticoagulant Therapy in Atrial Fibrillation Patients 27617088 2016 09 12 2018 11 13 2050-3369 5 2 2016 Aug Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. 102-9 10.15420/AER.2016.20.3 Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have emerged as alternatives to VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation. Four NOACS: dabigatran, apixaban (...) Intern Med. 1994 Jul 11;154(13):1449-57 8018000 Circulation. 2014 Mar 4;129(9):961-70 24323795 JAMA. 2001 May 9;285(18):2370-5 11343485 Atrial fibrillation apixaban dabigatran edoxaban non-vitamin K antagonist oral anticoagulants rivaroxaban stroke reduction 2016 9 13 6 0 2016 9 13 6 0 2016 9 13 6 1 ppublish 27617088 10.15420/AER.2016.20.3 PMC5013151

Arrhythmia & electrophysiology review2016 Full Text: Link to full Text with Trip Pro

214. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study

Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study 27434583 2018 10 01 2018 11 20 2380-6591 1 5 2016 08 01 JAMA cardiology JAMA Cardiol Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. 548-56 10.1001/jamacardio.2016.1445 Levels of fibroblast growth factor 23 (FGF23) are elevated in chronic kidney disease (...) (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death. Whether FGF23 is an independent risk factor for atrial fibrillation in CKD is unknown. To investigate the association of FGF23 with atrial fibrillation in CKD. Prospective cohort study of 3876 individuals with mild to severe CKD who enrolled in the Chronic Renal Insufficiency Cohort Study between June 19, 2003, and September 3, 2008, and were followed up through March 31, 2013. Baseline plasma FGF23 levels

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

215. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. 27463942 2016 09 22 2017 02 03 2380-6591 1 6 2016 Sep 01 JAMA cardiology JAMA Cardiol Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. 673-81 10.1001/jamacardio (...) .2016.1829 In the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, weight 60 kg or less, and creatinine level 1.5 mg/dL or higher-received a reduced dose of apixaban of 2.5 mg twice daily. Little is known about patients with 1 dose-reduction criterion who received the 5 mg twice daily dose of apixaban. To determine

JAMA cardiology2016

216. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. 27438322 2016 07 21 2017 02 03 2380-6591 1 4 2016 Jul 01 JAMA cardiology JAMA Cardiol Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. 451-60 10.1001/jamacardio.2016.1170 (...) Renal impairment confers an increased risk of stroke, bleeding, and death in patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in relation to renal function changes over time. To evaluate changes of renal function over time and their interactions with outcomes during a median of 1.8 years of follow-up in patients with atrial fibrillation randomized to apixaban vs warfarin treatment. The prospective, randomized, double-blind Apixaban for Reduction in Stroke

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

217. Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation.

Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. 27417598 2016 07 15 2016 07 15 2017 02 20 4 1 2016 Jan 14 Healthcare (Basel, Switzerland) Healthcare (Basel) Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. 10.3390/healthcare4010010 E10 This article describes the theoretical and pragmatic development of a patient-centred intervention for patients (...) with atrial fibrillation (AF). Theoretical models (Common Sense Model, Necessity-Concerns Framework), clinical frameworks, and AF patient feedback contributed to the design of a one-off hour-long behaviour-change intervention package. Intervention materials consisted of a DVD, educational booklet, diary and worksheet, which were patient-centred and easy to administer. The intervention was evaluated within a randomised controlled trial. Several "active theoretical ingredients" were identified (for e.g., where patients

Healthcare (Basel, Switzerland)2016 Full Text: Link to full Text with Trip Pro

218. Topera 3D mapping system (RhythmView Workstation and FIRMap) to guide ablation procedures for atrial fibrillation

Topera 3D mapping system (RhythmView Workstation and FIRMap) to guide ablation procedures for atrial fibrillation Topera 3D mapping system (RhythmView Workstation and FIRMap) to guide ablation procedures for atrial fibrillation Topera 3D mapping system (RhythmView Workstation and FIRMap) to guide ablation procedures for atrial fibrillation HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation HAYES, Inc.. Topera 3D mapping system (RhythmView Workstation and FIRMap) to guide ablation procedures for atrial fibrillation. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: The Topera 3D Rotor Mapping Solution, comprising the RhythmView Workstation and the FIRMap catheter, allows physicians to perform intraprocedural mapping of individualized rotors and other electrical sources

Health Technology Assessment (HTA) Database.2016

219. Genetic Investigation into the Paradoxical Differential Risk of Atrial Fibrillation Among Blacks and Whites

Genetic Investigation into the Paradoxical Differential Risk of Atrial Fibrillation Among Blacks and Whites 27438321 2018 10 09 2018 11 13 2380-6591 1 4 2016 07 01 JAMA cardiology JAMA Cardiol Genetic Investigation Into the Differential Risk of Atrial Fibrillation Among Black and White Individuals. 442-50 10.1001/jamacardio.2016.1185 White persons have a higher risk of atrial fibrillation (AF) compared with black individuals despite a lower prevalence of risk factors. This difference may be due (...) , at least in part, to genetic factors. To determine whether 9 single-nucleotide polymorphisms (SNPs) associated with AF account for this paradoxical differential racial risk for AF and to use admixture mapping to search genome-wide for loci that may account for this phenomenon. Genome-wide admixture analysis and candidate SNP study involving 3 population-based cohort studies that were initiated between 1987 and 1997, including the Cardiovascular Health Study (CHS) (n = 4173), the Atherosclerosis Risk

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

220. Risk of malignant cancer among women with new-onset atrial fibrillation

Risk of malignant cancer among women with new-onset atrial fibrillation 27438314 2018 10 09 2018 11 13 2380-6591 1 4 2016 07 01 JAMA cardiology JAMA Cardiol Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. 389-96 10.1001/jamacardio.2016.0280 A substantial proportion of patients with atrial fibrillation (AF) die of noncardiovascular causes, and recent studies suggest a link between AF and cancer. To evaluate the associations between AF and cancer in a large, long-term (...) prospective cohort study. In this cohort study, a total of 34 691 women 45 years or older and free of AF, cardiovascular disease, and cancer at baseline were prospectively followed up between 1993 and 2013, for incident AF and malignant cancer within the Women's Health Study, a randomized clinical trial of aspirin and vitamin E for the prevention of cardiovascular disease and cancer. Cox proportional hazards models using time-updated covariates were constructed to assess the association of new-onset AF

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro